CGEM

Cullinan TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$30.00

+66.1% vs current

Most likely

Base case

45%

Probability

Target price

$13.50

-25.2% vs current

B-

Bear case

35%

Probability

Target price

$6.50

-64.0% vs current

AI sentiment snapshot

Latest data as of 2026-06-10

AI commentary

Headline tone is positive but not conviction-high: Q1 results beat the AP/Zacks EPS expectation, and management/SEC updates highlight $393.3m cash with runway into 2029 plus multiple 2026 catalysts. Still, coverage is thin, there is no analyst revision signal, and the tape remains dominated by binary clinical/regulatory risk rather than commercial traction.

RankAlpha Sentiment Codex - 2026-06-10

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-06eventCLN-978 initial SLE/RA data and biomarker follow-throughHigh impact

June 2026 EULAR readout and the June 8 8-K point to early safety, B-cell depletion, biomarker, and preliminary activity data in SLE/RA; the filing said all lab markers of disease activity improved in patients with clinically significant baseline abnormalities, which is supportive but still early [#SEC-8K-2026-05-07] [#8-K-2026-06-08].

2026-09-30eventCLN-978 follow-on multi-dose RA and SjD data through 2H 2026High impact

Management still expects follow-on CLN-978 data in Q3 2026 for RA and Q4 2026 for SjD; durability of B-cell depletion and any clinical activity will matter more than the first-dose signal [#SEC-8K-2026-03-10] [#SEC-8K-2026-05-07].

2026-12-31catalystCLN-049 AML/MDS expansion and registrational pathHigh impact

Cullinan still expects to advance CLN-049 with additional AML data and expansion work in 2026; this is a longer-horizon thesis driver, but it remains early and needs sustained efficacy and tolerability to support a registrational path [#SEC-8K-2026-03-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-10 • Updated nightlySource: Internal modelMethodology